Evidence map›Paper›PMID 40834999›Full record

ArticleJournal of advanced research2026

METTL3 mediates m

Xuejie Fei, Caiyu Li, Jie Bai, Yu Xu, Ruihua Hu, Xingxing Wang, Yan Pan, Xinrui Zhu, Kequan Chen, Aidong Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuejie FeiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China; Department of Anesthesiology and Perioperative medicine, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
Caiyu LiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Jie BaiKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Yu XuKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Ruihua HuKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Xingxing WangKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Yan PanKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Xinrui ZhuCollege of Physical Education and Health, East China Normal University, Shanghai 200241, China.
Kequan ChenThe Second Clinical Medical School, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Aidong ChenKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Electronic address: aidongchen@njmu.edu.cn.
Lei ZhangDepartment of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China. Electronic address: zhangleimz@qduhospital.cn.
Ying HanKey Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Electronic address: yhancn@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFeatures of hypertension include imbalance between vascular relaxation and constriction along with vascular remodeling caused by endothelial dysfunction, further increasing peripheral resistance and blood pressure (BP). While N

objectivesThis study was to examine roles of METTL3-m

methodsWe generated METTL3 conditional endothelial cell (EC) knockdown (EKD) mice as well as various EKD or EC overexpression (EOE) mice. We implanted mice with subcutaneous osmotic minipumps containing angiotensin II (Ang II) to induce hypertension and tested parameters of cardiovascular function and remodeling.

resultsCompared to controls, METTL3 expression and m

conclusionMETTL3-EKD reduces BP and vasoconstriction and prevents cardiovascular remodeling by inhibiting the suppression of ADAM17 in ECs on the ACE2-Ang-(1-7) axis, and then improving Ang II-impaired endothelial function. This study may offer a novel prospective diagnostic or therapeutic strategy for hypertension.

Indexed as

ADAM17 ProteinAngiotensin-Converting Enzyme 2Angiotensin IHypertensionMethyltransferasesPeptide FragmentsPeptidyl-Dipeptidase AAdenosineAngiotensin IIAnimalsBlood PressureDisease Models, AnimalDisease ProgressionDown-RegulationEndothelial CellsHumansACE2 protein, humanAce2 protein, mouseADAM17 ProteinADAM17 protein, humanAdam17 protein, mouseAdenosineAngiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)Angiotensin IIMethyltransferasesMETTL3 protein, humanMettl3 protein, mouseN-methyladenosinePeptide FragmentsPeptidyl-Dipeptidase AADAM17–ACE2–Ang-(1–7) axisEndothelial dysfunctionHypertensionM(6)AMETTL3

Identifiers

PMID40834999
PMCPMC13131437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.